KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $129.0 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) rose 2.10% to $131.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.1 million, marking a year-over-year increase of 2.10%. This contributed to the annual value of $129.0 million for FY2024, which is 2.78% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) is $129.0 million, which was up 2.78% from $125.5 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $129.0 million during FY2024, and registered a low of $116.2 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $125.8 million, with a median of $125.5 million in 2023.
  • Data for Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY rose of 4.21% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $116.2 million in 2020, then grew by 2.94% to $119.6 million in 2021, then increased by 2.87% to $123.0 million in 2022, then grew by 2.00% to $125.5 million in 2023, then increased by 2.78% to $129.0 million in 2024.